TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15327428
Drug: r‐halphaGalA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐halphaGalA (1 mg/kg body weight) administered separately in the interval between dialysis treatments
Study: 9158882
Drug: Ormaplatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ormaplatin (30 min intravenous infusion)
Study: 3669756
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment with recombinant alpha 2b-interferon for 6 months after initial 12 months.
Study: 3669756
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after initial 12 months of interferon therapy.
Study: 28681267
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen (800 mg in 100 ml normal saline)
Study: 28681267
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (1 g in 100 ml normal saline)
Study: 16081469
Drug: Micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplementation (high-dose combination of calcium, magnesium, zinc, copper, selenium, vitamin A, thiamine, riboflavin, vitamin B6, folate, vitamin B12, vitamin C, vitamin E, vitamin D, Coenzyme Q10) for 9 months
Study: 10400846
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of fexofenadine HCl twice daily
Study: 10400846
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of sustained‐release pseudoephedrine HCl twice daily
Study: 10400846
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of fexofenadine HCl/120 mg of sustained‐release pseudoephedrine HCl twice daily
Study: 7477169
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus intensive chemotherapy and autologous bone marrow transplantation
Study: 7477169
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without transplantation
Study: 219470
Drug: procetofen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: procetofen (3 x 100 mg/day for 4-6 weeks)
Study: 27406859
Drug: Tomato products
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato products containing 30 mg lycopene per day
Study: 25564179
Drug: Peritonsillar infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar infiltration of ketamine 1.0 mg/kg added to peritonsillar tramadol 2 mg/kg
Study: 25564179
Drug: Peritonsillar saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar saline and peritonsillar infiltration of tramadol 2 mg/kg
Study: 21181914
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (0-6 month schedule)
Study: 19793040
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application (clindamycin, dexamethasone)
Study: 19793040
Drug: Systemic application
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic application (cefprozil, amoxicillin+clavulanate)
Study: 19793040
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no medications except analgesic)
Study: 17382220
Drug: Alvimopan 12
Normalized name: alvimopan 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan 12 mg administered 30 minutes or more preoperatively and twice daily postoperatively until hospital discharge (7 or fewer postoperative days)
Study: 15041504
Drug: Tramadol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol plus acetaminophen (APAP) 37.5 mg tramadol plus 325 mg APAP (n = 98)
Study: 15041504
Drug: Tramadol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol plus acetaminophen (APAP)
Study: 15041504
Drug: Codeine 30
Normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine 30 mg plus APAP 300 mg (n = 109)
Study: 15041504
Drug: Codeine plus
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine plus acetaminophen (APAP)
Study: 7905919
Drug: lorazepam (.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam (.05 mg/kg)
Study: 7905919
Drug: diazepam (.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (.25 mg/kg)
Study: 7905919
Drug: midazolam (.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam (.1 mg/kg)
Study: 2567114
Drug: Dilevalol (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (200, 400, 800, 1,600 mg)
Study: 2567114
Drug: Metoprolol (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100, 200, 300, 400 mg)
Study: 2567114
Drug: Dilevalol (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (100, 200, 400, 800 mg)
Study: 5312322
Drug: Isoniazid (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (5 mg/kg body-weight daily)
Study: 28467383
Drug: Total urinary
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total urinary polyphenol excretion (TPE) measured by the Folin‐Ciocalteu method
Study: 16563521
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 to 20 mg/d)
Study: 16563521
Drug: Olanzapine-fluoxetine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine-fluoxetine combination (6 and 25, 6 and 50, or 12 and 50 mg/d)
Study: 12878921
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 microg/kg twice daily for 8 weeks)
Study: 10719404
Drug: Pecan treatment
Normalized name: Pecan
DrugBank: Pecan (DB10555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pecan treatment group (68 g pecans per day for 8 weeks)
Study: 10719404
Drug: Pecan treatment
Normalized name: Pecan
DrugBank: Pecan (DB10555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pecan treatment group
Study: 1358119
Drug: (-)-3PPP (preclamol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-3PPP (preclamol) administered intramuscularly at doses of 30-40 mg
Study: 24571169
Drug: Probiotics, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics, taken twice a day for 2 weeks before surgery
Study: 24571169
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken twice a day for 2 weeks before surgery
Study: 22753904
Drug: Dose-escalated cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-escalated cetuximab (500 mg/m2 per week)
Study: 22753904
Drug: Standard-dose cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard-dose cetuximab (400 mg/m2 initial dose, then 250 mg/m2 per week)
Study: 22753904
Drug: Dose-escalated cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-escalated cetuximab (500 mg/m2 per week) in KRAS wild-type tumors
Study: 22753904
Drug: Standard-dose cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard-dose cetuximab (400 mg/m2 initial dose, then 250 mg/m2 per week) in KRAS wild-type tumors
Study: 20444847
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy with carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 15-3 monitoring
Study: 12114886
Drug: Duloxetine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (all doses) in severe cases
Study: 11035129
Drug: Tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaprofenic acid (300 mg b.d.)
Study: 11035129
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg t.d.s.)
Study: 8633584
Drug: Regimen 1
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 1 (B 150 mg q.i.d., OT 500 mg q.i.d., M 400 mg t.i.d. for 10 days and R 300 mg b.i.d. for 4 wk)
Study: 8633584
Drug: Ranitidine (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (during therapy)
Study: 26176643
Drug: Aliskiren (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150-300 mg)/Amlodipine (5 mg) (ALI/AML group, n=53)
Study: 26176643
Drug: High-dose Amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Amlodipine (10 mg) (h-dAML group, n=52)
Study: 17470315
Drug: ondansetron (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (0.25 mg, 1 mg, or 4 mg b.i.d.)
Study: 30094885
Drug: Vaginal washing
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal washing before intravaginal dinoprostone insertion (10 mg dinoprostone via Propess system)
Study: 26990824
Drug: Early integrated
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early integrated ART initiation during TB treatment
Study: 26990824
Drug: Late integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late integrated ART initiation during TB treatment
Study: 26990824
Drug: Delayed ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed ART initiation after TB treatment completion
Study: 20048658
Drug: Intraoperative thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative thoracic epidural bupivacaine perfusion (0.5% at 3 mL/hr) with preoperative intrathecal morphine (0.5 mg) and fentanyl (15 microg)
Study: 12472591
Drug: Subcutaneous lenograstim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous lenograstim during the first 12 weeks of standard immunosuppressive therapy
Study: 12472591
Drug: Standard immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppressive therapy (control group)
Study: 8749707
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulins (IVIg)
Study: 8749707
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange (PE) and Intravenous immune globulins (IVIg)
Study: 8749707
Drug: Single therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single therapy (either PE or IVIg)
Study: 8749707
Drug: Second cycle
Normalized name: 60 Second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second cycle of therapy (either PE or IVIg)
Study: 324571
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of cephazolin
Study: 324571
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of cephazolin plus a five-day course postoperatively
Study: 29205165
Drug: Targeted prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted prophylactic antibiotic regime (Group 2, n=144)
Study: 29205165
Drug: Targeted prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted prophylactic antibiotic regime (Group 2)
Study: 25726497
Drug: Active DBS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active DBS treatment
Study: 25726497
Drug: Sham DBS
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sham DBS treatment
Study: 19804515
Drug: Adenosine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (12 mg)
Study: 11783325
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional Chinese and Western medicine (TCM-WM) treatment including prednisone, Cytoxan (CTX), and Chinese medicinal herbs according to Syndrome-type.
Study: 11783325
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with Western medicine (WM) alone.
Study: 11783325
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional Chinese and Western medicine (TCM-WM) treatment.
Study: 3899240
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMW heparin) 1850 APTT units (7500 antifactor Xa units)
Study: 3899240
Drug: Unfractionated (UF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated (UF) calcium heparin 10000 APTT units
Study: 3899240
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of LMW heparin every day
Study: 30382820
Drug: Birth weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth weight of > 3600 g
Study: 24068750
Drug: Combined cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cognitive-behavioral psychotherapy (14 one-hour weekly sessions)
Study: 24068750
Drug: Conventional cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cognitive-behavioral psychotherapy (14 one-hour weekly sessions)
Study: 22673017
Drug: Tetrahydrobiopterin (BH(4))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrahydrobiopterin (BH(4)) 10 mg·kg(‐1) body weight
Study: 19001248
Drug: Carisbamate 300
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisbamate 300 mg/d
Study: 19001248
Drug: Carisbamate 800
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisbamate 800 mg/d
Study: 19001248
Drug: Carisbamate 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carisbamate 1,600 mg/d
Study: 15746990
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss with normal calcium intake (1 g/day)
Study: 15746990
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss with high calcium intake (1.7 g/day)
Study: 15746990
Drug: Weight maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight maintenance with normal calcium intake (1 g/day)
Study: 2141110
Drug: Sequential ultrafiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential ultrafiltration (UF; 1 litre/h)
Study: 2141110
Drug: Sequential ultrafiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential ultrafiltration (UF) during BC-UF
Study: 2141110
Drug: Sequential ultrafiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential ultrafiltration (UF)
Study: 6109648
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (500 mg every eight hours for a maximum of three days during menstruation for three consecutive cycles)
Study: 24534317
Drug: Remifentanyl and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanyl and propofol injection (Group A)
Study: 24534317
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride (Group B)
Study: 20376076
Drug: nebivolol (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebivolol (5-10 mg/day) for 8 weeks
Study: 12699210
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glucocorticoid and beta‐agonist (n = 52)
Study: 12699210
Drug: Beta‐agonist alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐agonist alone (n = 11)
Study: 9378464
Drug: Cytotoxic chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic chemotherapy (CT) for ALL
Study: 7901258
Drug: Dapiprazole administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapiprazole administered as directed by its manufacturer after pupil dilation with proparacaine 0.5%, hydroxyamphetamine 1.0%, and tropicamide 0.25%.
Study: 3961029
Drug: S-adenosyl-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-methionine (SAMe) 400 mg single dose and seven daily administrations
Study: 3961029
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with monoamine oxidase inhibitors (MAOIs)
Study: 20705561
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus trastuzumab (H0648g)
Study: 20705561
Drug: Chemotherapy (Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Control in H0648g)
Study: 20705561
Drug: Trastuzumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab monotherapy (H0649g)
Study: 20705561
Drug: Trastuzumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab monotherapy (H0650g)
Study: 15928305
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) treatment (8-10 mg/kg of body weight; 661 participants)
Study: 15928305
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (624 participants)
Study: 12595838
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg per day, increased to 150 mg per day after 411 patients enrolled)
Study: 3048075
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g glucose and 40 g fat
Study: 3048075
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g fructose and 40 g fat
Study: 3048075
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g sucrose and 40 g fat
Study: 3048075
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g fat alone
Study: 31609930
Drug: Bictegravir, Emtricitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) 50/200/25 mg
Study: 27000071
Drug: TENS therapy
Normalized name: Walgreens Electronic TENS Therapy Pain Relief Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS therapy for 10 weeks
Study: 27000071
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no TENS therapy)
Study: 16028147
Drug: Standard 4-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 4-dose course of dihydroartemisinin-piperaquine (DP4)
Study: 16028147
Drug: Once-daily regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily regimen of dihydroartemisinin-piperaquine (DP3)
Study: 11824390
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiotherapy with cisplatin based chemotherapy
Study: 11824390
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiotherapy with hyperthermia
Study: 11824390
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiotherapy, cisplatin, and hyperthermia
Study: 8308183
Drug: Oral cat
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cat immunotherapy (2.5 x 10(6) allergy units or 436 U Fel d I administered over 3 months)
Study: 8308183
Drug: Oral cat
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cat immunotherapy
Study: 1092131
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous iron 2000 mg after each blood donation
Study: 1092131
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous iron 1000 mg after each blood donation
Study: 1092131
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous iron 2000 mg after four months between donations
Study: 31612475
Drug: Minimal oral
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal oral intake during nutrition support
Study: 31612475
Drug: Additional beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional beta lactam antibiotics
Study: 26690313
Drug: BND 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: BND 600 mg
Study: 26690313
Drug: BND 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BND 1,200 mg
Study: 25155931
Drug: Combined OPRM1
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined OPRM1 118A>G and COMT 472G>A genotype
Study: 20460233
Drug: HMB (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB (2 g/d)
Study: 7486087
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 5 micrograms/mL
Study: 7486087
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 10 micrograms/mL
Study: 7851059
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily activity
Study: 31655508
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg tablet given the night before and 1 hour before the operation)
Study: 31655508
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg tablet)
Study: 24121184
Drug: 50:40:10 mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50:40:10 mixture of MCT, soybean oil, and fish oil (treatment)
Study: 17298423
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus add-on omalizumab
Study: 14517707
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 3-202 50 mg
Study: 14517707
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 3-202 100 mg